Technical Analysis for RGEN - Repligen Corporation
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| D | 176.03 | 2.06% | 3.55 |
Earnings due: May 16
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Flat | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Resistance | Bearish | 0.00% | |
| Stochastic Reached Overbought | Strength | 0.00% | |
| Weak + Overbought | Other | 0.00% | |
| Above Upper BB | Strength | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Overbought Stochastic | Strength | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 2.06% | |
| Crossed Above 200 DMA | Bullish | 2.06% | |
| Multiple of Ten Bullish | Other | 2.06% |
| Alert | Time |
|---|---|
| Upper Bollinger Band Resistance | about 16 hours ago |
| Rose Above Previous Day's High | about 16 hours ago |
| Rose Above Upper Bollinger Band | about 16 hours ago |
| Up 2% | about 16 hours ago |
| Up 1% | about 16 hours ago |
Free Daily (Stock) Chart Reading
- Earnings date: 05/16/2024
Repligen Corporation Description
Repligen Corporation, a life sciences company, engages in the development, production, and commercialization of consumable products used in the process of manufacturing biological drugs. Its bioprocessing products are sold to various life sciences and biopharmaceutical companies worldwide. The company manufactures Protein A, a critical reagent used to separate and purify monoclonal antibody therapeutics. It also supplies various growth factor products used to increase cell culture productivity during the fermentation stage of drug manufacturing. In addition, the company develops and markets its OPUS brand series of pre-packed plug-and-play' chromatography columns, and provides ELISA test kits to ensure final product quality. Further, Repligen has a portfolio of clinical-stage partnering assets, including a pancreatic imaging agent in Phase 3 development and a orphan drug candidate in Phase 1 development. The company was founded in 1981 and is headquartered in Waltham, Massachusetts.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Natural Sciences Monoclonal Antibody 3 D Orphan Drug Consumable Products Chromatography Imaging Agent Bioprocessing Cell Culture Bioprocess Drug Manufacturing Growth Factor Products
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 211.13 |
| 52 Week Low | 110.46 |
| Average Volume | 451,535 |
| 200-Day Moving Average | 170.70 |
| 50-Day Moving Average | 176.87 |
| 20-Day Moving Average | 165.50 |
| 10-Day Moving Average | 167.82 |
| Average True Range | 6.04 |
| RSI (14) | 57.63 |
| ADX | 19.6 |
| +DI | 25.63 |
| -DI | 22.47 |
| Chandelier Exit (Long, 3 ATRs) | 158.82 |
| Chandelier Exit (Short, 3 ATRs) | 169.94 |
| Upper Bollinger Bands | 175.29 |
| Lower Bollinger Band | 155.70 |
| Percent B (%b) | 1.04 |
| BandWidth | 11.83 |
| MACD Line | -1.31 |
| MACD Signal Line | -3.11 |
| MACD Histogram | 1.7996 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 182.65 | ||||
| Resistance 3 (R3) | 182.21 | 179.58 | 181.54 | ||
| Resistance 2 (R2) | 179.58 | 177.89 | 179.79 | 181.17 | |
| Resistance 1 (R1) | 177.80 | 176.85 | 178.69 | 178.24 | 180.81 |
| Pivot Point | 175.17 | 175.17 | 175.61 | 175.38 | 175.17 |
| Support 1 (S1) | 173.39 | 173.48 | 174.28 | 173.83 | 171.25 |
| Support 2 (S2) | 170.76 | 172.44 | 170.97 | 170.89 | |
| Support 3 (S3) | 168.98 | 170.76 | 170.52 | ||
| Support 4 (S4) | 169.42 |
